Literature DB >> 27118389

Management of Small Vessel Vasculitides.

Giuseppe Lopalco1, Donato Rigante2, Vincenzo Venerito1, Giacomo Emmi3, Maria Grazia Anelli1, Giovanni Lapadula1, Florenzo Iannone1, Luca Cantarini4,5.   

Abstract

Inflammation mediated by cells of the immune system and necrosis are the most striking features observed at the histologic level in patients with vasculitides, clinical entities classified according to pathologic findings involving different organs, to etiology, or to size of vessels involved. Small vessel vasculitides (SVV) are a peculiar group of systemic disorders electively involving small intraparenchymal arteries, arterioles, capillaries, or venules and leading to different levels of vascular obstruction, tissue ischemia and risk of infarction; they can be divided into anti-neutrophil cytoplasmic antibody-associated vasculitides and immune complex vasculitides. Despite the significant advances in understanding the whole disease process and pathophysiology of SVV, strong efforts are still needed to draft, share and spread guidelines in the therapeutic management of these protean disorders. After an accurate evaluation of different open or double-blind trials and cohort studies in this review, we analyze the actual medical tools suggested for treating granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, Henoch-Schönlein purpura, cryoglobulinemic vasculitis, anti-glomerular basement membrane disease and hypocomplementemic urticarial vasculitis.

Entities:  

Keywords:  Biologics; Immunosuppressive agents; Therapy; Vasculitides

Mesh:

Substances:

Year:  2016        PMID: 27118389     DOI: 10.1007/s11926-016-0580-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  92 in total

1.  Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database.

Authors:  Christian Pagnoux; Muriel Stubbe; François Lifermann; Olivier Decaux; Michel Pavic; Alice Bérezné; Isabelle Delacroix-Szmania; Nadine Méaux-Ruault; Boris Bienvenu; Jean Cabane; Loïc Guillevin
Journal:  J Rheumatol       Date:  2010-12-01       Impact factor: 4.666

2.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

Authors:  Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Véronique Le Guern; Marie-Hélène André; Martine Gayraud; David Jayne; Daniel Blöckmans; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2007-05-15

3.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

4.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

5.  Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.

Authors:  Christian Pagnoux; Thomas Quéméneur; Jacques Ninet; Elisabeth Diot; Xavier Kyndt; Benoît de Wazières; Jean-Luc Reny; Xavier Puéchal; Pierre-Yves le Berruyer; Olivier Lidove; Philippe Vanhille; Pascal Godmer; Olivier Fain; Daniel Blockmans; Boris Bienvenu; Florence Rollot; Séverine Aït el Ghaz-Poignant; Alfred Mahr; Pascal Cohen; Luc Mouthon; Elodie Perrodeau; Philippe Ravaud; Loïc Guillevin
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

Review 6.  Goodpasture's syndrome: a clinical update.

Authors:  Antonio Greco; Maria Ida Rizzo; Armando De Virgilio; Andrea Gallo; Massimo Fusconi; Giulio Pagliuca; Salvatore Martellucci; Rosaria Turchetta; Lucia Longo; Marco De Vincentiis
Journal:  Autoimmun Rev       Date:  2014-11-15       Impact factor: 9.754

Review 7.  The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions.

Authors:  E R Popa; J W Cohen Tervaert
Journal:  Intern Med       Date:  2003-09       Impact factor: 1.271

Review 8.  Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications.

Authors:  G De Rosa; M Pardeo; D Rigante
Journal:  Eur Rev Med Pharmacol Sci       Date:  2007 Sep-Oct       Impact factor: 3.507

9.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

10.  Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.

Authors:  Donato Rigante; Piero Valentini; Daniela Rizzo; Andrea Leo; Gabriella De Rosa; Roberta Onesimo; Alessia De Nisco; Donatella Francesca Angelone; Adele Compagnone; Angelica Bibiana Delogu
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

View more
  4 in total

Review 1.  Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives.

Authors:  Lucio Manenti; Maria Letizia Urban; Federica Maritati; Maricla Galetti; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

2.  An unusual presentation of eosinophilic angiocentric fibrosis.

Authors:  Joel Hardman; Christopher Toon; Arjuna Nirmalananda
Journal:  J Surg Case Rep       Date:  2017-12-08

3.  Aortic valve replacement due to granulomatosis with polyangiitis: a case series.

Authors:  Gilles Uijtterhaegen; Laura De Donder; Eline Ameloot; Kristof Lefebvre; Jo Van Dorpe; Michel De Pauw; Katrien François
Journal:  Eur Heart J Case Rep       Date:  2020-10-06

Review 4.  Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.

Authors:  Priya Veluswamy; Max Wacker; Maximilian Scherner; Jens Wippermann
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.